DOCSLIB.ORG

(CELF1), an RNA Binding Protein

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(CELF1), an RNA Binding Protein ROLES OF CUG-BP, ELAV-LIKE FAMILY MEMBER 1 (CELF1), AN RNA BINDING PROTEIN, DURING VERTEBRATE HEART DEVELOPMENT by YOTAM N. BLECH-HERMONI Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Advisor: Dr. Andrea N. Ladd Program in Cell Biology, Department of Molecular Biology and Microbiology, School of Medicine CASE WESTERN RESERVE UNIVERSITY January 2015 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of Yotam N. Blech-Hermoni Candidate for the degree of Doctor of Philosophy*. Committee Chair Dr. Donna M. Driscoll Committee Member Dr. Alan M. Tartakoff Committee Member Dr. Hua Lou Date of Defense November 20, 2014 *Published material is included in accordance with contracts and stipulations set forth by the publishers. i Table of Contents List of Tables ........................................................................................................................... vii List of Figures ........................................................................................................................ viii Acknowledgements ................................................................................................................. x List of Abbreviations ............................................................................................................. xi Abstract ................................................................................................................................... xiv Chapter 1: Introduction ........................................................................................................ 1 1.1. Post-transcriptional regulation of gene expression ............................................................ 1 1.2. The CUG-BP, Elav-like family (CELF) of proteins ................................................................. 2 1.2.1. Nomenclature ........................................................................................................................ 3 1.2.2. Structure and RNA binding .............................................................................................. 6 1.2.3. The ‘Divergent Domain’ .................................................................................................... 9 1.2.4. Expression patterns and roles ....................................................................................... 9 1.3. CELF1 ................................................................................................................................................... 10 1.3.1. Roles in the cytoplasm .................................................................................................... 11 1.3.2. Roles in the nucleus ......................................................................................................... 13 1.3.3. Biological functions of CELF1 ...................................................................................... 15 1.3.4. Mouse models for the study of CELF1 ..................................................................... 17 1.4. Model organisms ............................................................................................................................. 17 1.4.1. The mouse ............................................................................................................................ 18 1.4.2. The chicken .......................................................................................................................... 20 1.4.3. The frog ................................................................................................................................. 21 1.4.4. Comparative staging ........................................................................................................ 22 ii 1.5. The current work ............................................................................................................................ 22 Chapter 2: Materials and Methods .................................................................................. 24 2.1. Animal use .......................................................................................................................................... 24 2.2. Chickens ............................................................................................................................................... 24 2.3. Chicken embryonic tissue and embryo collection ............................................................. 24 2.4. Chicken embryonic primary cardiomyocyte isolation and culture ........................... 25 2.5. Transfection of primary embryonic cardiomyocytes with siRNAs ............................ 26 2.6. EdU staining of cultured primary cardiomyocytes .......................................................... 27 2.7. Mice ....................................................................................................................................................... 28 2.8. Mouse embryo collection ............................................................................................................. 29 2.9. Western blotting and nuclear-cytoplasmic fractionation of tissues ........................ 29 2.10. Immunofluorescence [IF] .......................................................................................................... 31 2.11. In situ hybridization .................................................................................................................... 32 2.12. Semi-quantitative RT-PCR ........................................................................................................ 33 2.13. Real-time RT-PCR ......................................................................................................................... 33 2.14. Cross-linking immunoprecipitation (CLIP) ....................................................................... 36 2.15. Analysis of CLIP tags ................................................................................................................... 38 2.16. Frog embryo production ........................................................................................................... 39 2.17. Frog embryo morpholino oligonucleotide (MO) microinjection ............................. 40 2.18. Whole-mount immunohistochemistry [IHC] and IF ...................................................... 41 2.19. Bright-field imaging .................................................................................................................... 42 2.20. Frog construct design ................................................................................................................. 42 2.21. Alternative Splicing Assay ........................................................................................................ 43 iii Chapter 3: RNA binding proteins in the regulation of heart development ....... 45 3.1. Introduction ...................................................................................................................................... 45 3.2. Cardiac cell fate, heart tube formation, and differentiation ........................................ 48 3.2.1. Formation of the heart tube ......................................................................................... 53 3.2.2. RBPs in cardiomyocyte differentiation and myofibril development .......... 56 3.3. Cardiac morphogenesis ................................................................................................................ 59 3.3.1. Endocardial cushion development ............................................................................ 60 3.3.2. Myocardial trabeculation and compaction ............................................................ 63 3.4. Postnatal maturation of the heart .......................................................................................... 64 3.4.1. CELF- and MBNL-mediated alternative splicing programs ............................ 65 3.4.2. Roles of the SR protein family in the maturing heart ........................................ 67 3.5. Developmental dysregulation and disease .......................................................................... 69 3.5.1. RNA binding proteins and congenital heart defects .......................................... 70 3.5.2. The recapitulation of fetal programs during adult heart disease ................ 71 3.6. Concluding remarks ....................................................................................................................... 73 3.7. Acknowledgements ......................................................................................................................... 76 Chapter 4: Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development .............................................. 77 4.1. Introduction ...................................................................................................................................... 77 4.2. Results and Discussion .................................................................................................................. 80 4.2.1. CELF1 and CELF2 undergo dynamic post-transcriptional regulation during early heart development in chicken ...................................................................... 80 4.2.2. Different CELF1 and CELF2 isoforms are expressed in different tissues . 88 iv 4.2.3. Regional distribution of CELF1 and CELF2 in the chicken embryo differ between tissues
Load more

Recommended publications
  • NIH Public Access Author Manuscript Pharmacogenet Genomics
    NIH Public Access Author Manuscript Pharmacogenet Genomics. Author manuscript; available in PMC 2012 September 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacogenet Genomics. 2011 September ; 21(9): 607–613. doi:10.1097/FPC.0b013e3283415515. PharmGKB summary: very important pharmacogene information for PTGS2 Caroline F. Thorna, Tilo Grosserc, Teri E. Kleina, and Russ B. Altmana,b aDepartment of Genetics, Stanford University Medical Center, Stanford, California bDepartment of Bioengineering, Stanford University Medical Center, Stanford, California cInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, Pennsylvania, USA Keywords cyclooxygenase-2; coxibs; non-steroidal anti-inflammatory drugs; pharmacogenomics; PTGS2; rs20417; rs5275; rs689466 Very important pharmacogene: PTGS2 This PharmGKB summary briefly discusses the PTGS2 gene and current understanding of its function, structure, regulation, and pharmacogenomic relevance. We also present three variants with pharmacogenomic significance and highlight the gaps in our knowledge of PTGS2-drug interactions. Overview The PTGS2 gene codes for prostaglandin G/H synthase-2, which catalyses the first two steps in the metabolism of arachadonic acid. Prostaglandin G/H synthase-2 has two active sites, a hydroperoxidase and a cyclooxygenase (COX) site, and is colloquially termed COX-2. The bifunctional enzyme performs the bis-dioxygenation and reduction of arachadonic acid to form prostaglandin (PG)G2 and H2. PGH2 is then converted to other PGs that modulate inflammation, including PGD2, PGE2, PGF2α, PGI2, and thromboxane A2 (This pathway is shown in the Lipid maps database at http://www.lipidmaps.org/data/IntegratedPathways Data/SetupIntegratedPathways.pl? imgsize=730&Mode=RAW2647&DataType=FAEicosanoidsMedia). COX-2 is the target for nonsteroidal anti-inflammatory drugs (NSAIDS) including those that were purposefully designed (pd) to be selective for COX-2 (pdNSAIDs or coxibs).
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Regulation of Pluripotency by RNA Binding Proteins
    Cell Stem Cell Review Regulation of Pluripotency by RNA Binding Proteins Julia Ye1,2 and Robert Blelloch1,2,* 1The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Center for Reproductive Sciences, University of California, San Francisco, San Francisco, CA 94143, USA 2Department of Urology, University of California, San Francisco, San Francisco, CA 94143, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.stem.2014.08.010 Establishment, maintenance, and exit from pluripotency require precise coordination of a cell’s molecular machinery. Substantial headway has been made in deciphering many aspects of this elaborate system, particularly with respect to epigenetics, transcription, and noncoding RNAs. Less attention has been paid to posttranscriptional regulatory processes such as alternative splicing, RNA processing and modification, nuclear export, regulation of transcript stability, and translation. Here, we introduce the RNA binding proteins that enable the posttranscriptional regulation of gene expression, summarizing current and ongoing research on their roles at different regulatory points and discussing how they help script the fate of pluripotent stem cells. Introduction RBPs are responsible for every event in the life of an RNA Embryonic stem cells (ESCs), which are derived from the inner molecule, including its capping, splicing, cleavage, nontem- cell mass of the mammalian blastocyst, are remarkable because plated nucleotide addition, nucleotide editing, nuclear export, they can propagate in vitro indefinitely while retaining both the cellular localization, stability, and translation (Keene, 2007). molecular identity and the pluripotent properties of the peri-im- Overall, little is known about RBPs: most are classified based plantation epiblast.
    [Show full text]
  • RBM9 Antibody (Monoclonal) (M02) Mouse Monoclonal Antibody Raised Against a Partial Recombinant RBM9
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 RBM9 Antibody (monoclonal) (M02) Mouse monoclonal antibody raised against a partial recombinant RBM9. Catalog # AT3594a Specification RBM9 Antibody (monoclonal) (M02) - Product Information Application IF, WB, E Primary Accession O43251 Other Accession BC013115 Reactivity Human, Mouse Host mouse Clonality Monoclonal Isotype IgG2b Kappa Calculated MW 41374 RBM9 Antibody (monoclonal) (M02) - Additional Information Immunofluorescence of monoclonal antibody to RBM9 on A-431 cell. [antibody concentration 10 ug/ml] Gene ID 23543 Other Names RNA binding protein fox-1 homolog 2, Fox-1 homolog B, Hexaribonucleotide-binding protein 2, RNA-binding motif protein 9, RNA-binding protein 9, Repressor of tamoxifen transcriptional activity, RBFOX2, FOX2, HRNBP2, RBM9, RTA Target/Specificity RBM9 (AAH13115, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Dilution Antibody Reactive Against Recombinant WB~~1:500~1000 Protein.Western Blot detection against Immunogen (36.63 KDa) . Format Clear, colorless solution in phosphate buffered saline, pH 7.2 . Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Precautions RBM9 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 RBM9 Antibody (monoclonal) (M02) - Protocols Provided below are standard protocols that you may find useful for product applications. • Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety RBM9 monoclonal antibody (M02), clone • Cell Culture 5E11 Western Blot analysis of RBM9 expression in A-431 ( (Cat # AT3594a ) RBM9 monoclonal antibody (M02), clone 5E11.
    [Show full text]
  • A Missense Mutation in the RSRSP Stretch of Rbm20 Causes Dilated
    www.nature.com/scientificreports OPEN A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fbrillation in mice Kensuke Ihara1,2*, Tetsuo Sasano2, Yuichi Hiraoka3, Marina Togo‑Ohno4, Yurie Soejima5, Motoji Sawabe5, Megumi Tsuchiya6, Hidesato Ogawa6, Tetsushi Furukawa1 & Hidehito Kuroyanagi4* Dilated cardiomyopathy (DCM) is a fatal heart disease characterized by left ventricular dilatation and cardiac dysfunction. Recent genetic studies on DCM have identifed causative mutations in over 60 genes, including RBM20, which encodes a regulator of heart‑specifc splicing. DCM patients with RBM20 mutations have been reported to present with more severe cardiac phenotypes, including impaired cardiac function, atrial fbrillation (AF), and ventricular arrhythmias leading to sudden cardiac death, compared to those with mutations in the other genes. An RSRSP stretch of RBM20, a hotspot of missense mutations found in patients with idiopathic DCM, functions as a crucial part of its nuclear localization signals. However, the relationship between mutations in the RSRSP stretch and cardiac phenotypes has never been assessed in an animal model. Here, we show that Rbm20 mutant mice harboring a missense mutation S637A in the RSRSP stretch, mimicking that in a DCM patient, demonstrated severe cardiac dysfunction and spontaneous AF and ventricular arrhythmias mimicking the clinical state in patients. In contrast, Rbm20 mutant mice with frame‑shifting deletion demonstrated less severe phenotypes, although loss of RBM20‑dependent alternative splicing was indistinguishable. RBM20S637A protein cannot be localized to the nuclear speckles, but accumulated in cytoplasmic, perinuclear granule‑like structures in cardiomyocytes, which might contribute to the more severe cardiac phenotypes. Dilated cardiomyopathy (DCM) is a fatal cardiac disease characterized by enlargement of the cardiac chambers and impaired systolic function1.
    [Show full text]
  • Insights from Conventional and Unconventional Myosins A
    Structure-Function Analysis of Motor Proteins: Insights from Conventional and Unconventional Myosins A Thesis SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Karl J. Petersen IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Margaret A. Titus, Advisor David D. Thomas, Co-Advisor December 2016 © Karl J. Petersen 2016 Acknowledgements This thesis would not exist without the patient support of my advisors, Meg Titus and Dave Thomas. Any shortcomings are my own. Collaborators Holly Goodson, Anne Houdusse, and Gant Luxton also provided invaluable training and support. I am also grateful for essential services provided by departmental staff: Sarah Blakely Anderson, Octavian Cornea, Sarah Dittrich, Karen Hawkinson, Michelle Lewis, Mary Muwahid, Laurie O’Neill, Darlene Toedter, with apologies to others not listed. Thanks to friends and colleagues at the University of Minnesota: Ashley Arthur, Kelly Bower, Brett Colson, Sinziana Cornea, Chi Meng Fong, Greg Gillispie, Piyali Guhathakurta, Tejas Gupte, Tom Hays, Norma Jiménez Ramírez, Dawn Lowe, Allison MacLean, Santiago Martínez Cifuentes, Jared Matzke, Megan McCarthy, Joachim Mueller, Joe Muretta, Kurt Peterson, Mary Porter, Ewa Prochniewicz, Mike Ritt, Cosmo Saunders, Shiv Sivaramakrishnan, Ruth Sommese, Doug Tritschler, Brian Woolums. i Abstract Myosin motor proteins play fundamental roles in a multitude of cellular processes. Myosin generates force on cytoskeletal actin filaments to control cell shape, most dramatically during cytokinesis, and has a conserved role in defining cell polarity. Myosin contracts the actin cytoskeleton, ensuring prompt turnover of cellular adhesion sites, retracting the cell body during migration and development, and contracting muscle among diverse other functions. How myosins work, and why force generation is essential for their function, is in many cases an open question.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Molecular Genetic Analysis of Rbm45/Drbp1: Genomic Structure, Expression, and Evolution Lauren E
    Journal of Student Research (2018) Volume 7, Issue 2, pp 49-61 Research Article Molecular Genetic Analysis of Rbm45/Drbp1: Genomic Structure, Expression, and Evolution Lauren E. Pricea,f, Abigail B. Loewen Faulb,f, Aleksandra Vuchkovskaa, Kevin J. Lopeza, Katie M. Fastb, Andrew G. Ecka, David W. Hoferera,e, and Jeffrey O. Hendersona,b,c,d,g RNA recognition motif-type RNA-binding domain containing proteins (RBDPs) participate in RNA metabolism including regulating mRNA stability, nuclear-cytoplasmic shuttling, and splicing. Rbm45 is an RBDP first cloned from rat brain and expressed spatiotemporally during rat neural development. More recently, RBM45 has been associated with pathological aggregates in the human neurological disorders amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer’s. Rbm45 and the neural developmental protein musashi-1 are in the same family of RDBPs and have similar expression patterns. In contrast to Musashi-1, which is upregulated during colorectal carcinogenesis, we found no association of RBM45 overexpression in human colon cancer tissue. In order to begin characterizing RNA-binding partners of Rbm45, we have successfully cloned and expressed human RBM45 in an Intein fusion-protein expression system. Furthermore, to gain a better understanding of the molecular genetics and evolution of Rbm45, we used an in silico approach to analyze the gene structure of the human and mouse Rbm45 homologues and explored the evolutionary conservation of Rbm45 in metazoans. Human RBM45 and mouse Rbm45 span ~17 kb and 13 kb, respectively, and contain 10 exons, one of which is non-coding. Both genes have TATA-less promoters with an initiator and a GC-rich element.
    [Show full text]
  • Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes
    2137 Genetic Variants and Prostate Cancer Risk: Candidate Replication and Exploration of Viral Restriction Genes Joan P. Breyer,1 Kate M. McReynolds,1 Brian L. Yaspan,2 Kevin M. Bradley,1 William D. Dupont,3 and Jeffrey R. Smith1,2,4 Departments of 1Medicine, 2Cancer Biology, and 3Biostatistics, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine; and 4Medical Research Service, VA Tennessee Valley Healthcare System, Nashville, Tennessee Abstract The genetic variants underlying the strong heritable at genome-wide association study loci 8q24, 11q13, and À À component ofprostate cancer remain largely unknown. 2p15 (P =2.9Â 10 4 to P =4.7Â 10 5), showing study Genome-wide association studies ofprostate cancer population power. We also find evidence to support have yielded several variants that have significantly reported associations at candidate genes RNASEL, replicated across studies, predominantly in cases EZH2, and NKX3-1 (P = 0.031 to P = 0.0085). We unselected for family history of prostate cancer. further explore a set of candidate genes related to Additional candidate gene variants have also been RNASEL and to its role in retroviral restriction, proposed, many evaluated within familial prostate identifying nominal associations at XPR1 and RBM9. cancer study populations. Such variants hold great The effects at 8q24 seem more pronounced for those potential value for risk stratification, particularly for diagnosed at an early age, whereas at 2p15 and early-onset or aggressive prostate cancer, given the RNASEL the effects were more pronounced at a later comorbidities associated with current therapies. Here, age. However, these trends did not reach statistical we investigate a Caucasian study population of523 significance.
    [Show full text]
  • C. Elegans GFP/RFP Alternative Splicing Screen
    ARTICLES Transgenic alternative-splicing reporters reveal tissue-specific expression profiles and regulation s d mechanisms in vivo o h t e 1,2 3,4 3,4 1,2 m Hidehito Kuroyanagi , Tetsuo Kobayashi , Shohei Mitani & Masatoshi Hagiwara e r u t a n / Alternative splicing of pre-mRNAs allows multicellular organisms native exons have been well characterized by analyzing model genes. m o c to create a huge diversity of proteomes from a finite number of Expression cloning strategies have permitted the global collection . e r genes. But extensive studies in vitro or in cultured cells have not of putative sequence elements that function in cultured cells, and u t a fully explained the regulation mechanisms of tissue-specific or bioinformatic analyses have identified putative cis elements within n . developmentally regulated alternative splicing in living exons and introns. Recently, however, conditional knockouts of w w organisms. Here we report a transgenic reporter system that trans-acting SR protein families revealed that alternative splicing of w / / : allows visualization of expression profiles of mutually exclusive only a few target genes are crucially dependent on a specific protein p t t exons in Caenorhabditis elegans. Reporters for egl-15 exons 5A in cardiac muscles, even though many more genes expressed in this h and 5B showed tissue-specific profiles, and we isolated mutants 14 p tissue have typical cis elements . This indicates that we cannot u o defective in the tissue specificity. We identified alternative- precisely predict the alternative splicing patterns in each tissue r G splicing defective-1 (asd-1), encoding a new RNA-binding or cell without the assessment of the regulation mechanisms in g protein of the evolutionarily conserved Fox-1 family, as a living organisms.
    [Show full text]
  • The Splicing Regulator Rbfox1 (A2BP1) Controls Neuronal Excitation in the Mammalian Brain
    LETTERS The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain Lauren T Gehman1, Peter Stoilov2, Jamie Maguire3, Andrey Damianov4, Chia-Ho Lin4, Lily Shiue5, Manuel Ares Jr5, Istvan Mody6,7 & Douglas L Black1,4,8 The Rbfox family of RNA binding proteins regulates alternative The three mouse Rbfox paralogues show a high degree of sequence splicing of many important neuronal transcripts, but its role in conservation, especially within the RNA binding domain, which is neuronal physiology is not clear1. We show here that central identical in Rbfox1 and Rbfox2 and is only slightly altered in Rbfox3 nervous system–specific deletion of the gene encoding Rbfox1 (94% amino acid identity). Rbfox1 is specifically expressed in neurons, results in heightened susceptibility to spontaneous and kainic heart and muscle6,18, whereas Rbfox2 is expressed in these tissues acid–induced seizures. Electrophysiological recording revealed and in other cell types, including the embryo, hematopoetic cells and a corresponding increase in neuronal excitability in the dentate embryonic stem cells6,19,20. Expression of Rbfox3 is limited to neu- gyrus of the knockout mice. Whole-transcriptome analyses rons21,22. In the mature brain, most neurons express all three Rbfox identified multiple splicing changes in the Rbfox1−/− brain with paralogs, but certain neuronal subtypes and sporadic individual cells few changes in overall transcript abundance. These splicing can be seen that express only one or two of the proteins23 (Fig. 1a). changes alter proteins that mediate synaptic transmission and All three proteins have similar N- and C-terminal domains that are membrane excitation. Thus, Rbfox1 directs a genetic program diversified by alternative promoter use and alternative splicing to required in the prevention of neuronal hyperexcitation and produce a cohort of related protein isoforms with variable localization seizures.
    [Show full text]
  • Expression of Normally Repressed Myosin Heavy Chain 7B in the Mammalian Heart Induces Dilated Cardiomyopathy Angela K
    ORIGINAL RESEARCH Expression of Normally Repressed Myosin Heavy Chain 7b in the Mammalian Heart Induces Dilated Cardiomyopathy Angela K. Peter, PhD;* Alberto C. Rossi, PhD;* Massimo Buvoli, MD, PhD; Christopher D. Ozeroff, BA; Claudia Crocini, PhD; Amy R. Perry, BS; Ada E. Buvoli, BS; Lindsey A. Lee, BS; Leslie A. Leinwand, PhD Background-—In mammals, muscle contraction is controlled by a family of 10 sarcomeric myosin motors. The expression of one of its members, MYH7b, is regulated by alternative splicing, and while the protein is restricted to specialized muscles such as extraocular muscles or muscle spindles, RNA that cannot encode protein is expressed in most skeletal muscles and in the heart. Remarkably, birds and snakes express MYH7b protein in both heart and skeletal muscles. This observation suggests that in the mammalian heart, the motor activity of MYH7b may only be needed during development since its expression is prevented in adult tissue, possibly because it could promote disease by unbalancing myocardial contractility. Methods and Results-—We have analyzed MYH7b null mice to determine the potential role of MYH7b during cardiac development and also generated transgenic mice with cardiac myocyte expression of MYH7b protein to measure its impact on cardiomyocyte function and contractility. We found that MYH7b null mice are born at expected Mendelian ratios and do not have a baseline cardiac phenotype as adults. In contrast, transgenic cardiac MYH7b protein expression induced early cardiac dilation in males with significantly increased left ventricular mass in both sexes. Cardiac dilation is progressive, leading to early cardiac dysfunction in males, but later dysfunction in females.
    [Show full text]